Stent thrombosis introduction
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview:
- Stent thrombosis (ST) is a rare but devastating complication of coronary artery stenting that is associated with a high rate of morbidity and mortality [1] [2] [3] [4]
- This process should not be confused with re-stenosis, a fibro-proliferative disorder which is associated with recurrent angina and ischemia but uncommonly with myocardial infarction or death.
Stent thrombosis with bare metal stent vs drug eluting stent:
- Over the years stent thrombosis of bare metal stents (BMS) has been minimised by refining stent design, adopting optimal stenting strategies and improved antiplatelet medication usage from a massive 24% in some studies to [5] a rare and acceptable 0.5-1.5% in the current environment.
- Following the approval by the FDA, the drug eluting stents (DES) largely replaced BMS, driven solely by the reduced revascularization with relatively little attention paid to the issue of ST.
- Increased usage of DES and continued presentation of patients with ST beyond the first few months of implantation, coupled with the widespread awareness of ST, have led to a steady and increased stream of reporting of ST in DES.
- Recent description of frequent subclinical insitu thrombus formation within DES in the coronaries by Katani et al[6], not only took the medical community by surprise but afforded a first hand in-vivo glimpse at the stent site itself.
Treatment:
- It should be noted that the term coronary stent thrombosis (ST) is commonly used for clinically significant episodes. [7]
- In this context, clinically significant ST appears to be a rare complication with devastating consequences if left untreated emergently, though the mileu for such probably exists in a much larger population.
References
- ↑ Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ; et al. (2001). "Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials". Circulation. 103 (15): 1967–71. PMID 11306525.
- ↑ Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A (1997). "Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome". J Am Coll Cardiol. 29 (1): 6–12. PMID 8996288.
- ↑ Karrillon GJ, Morice MC, Benveniste E, Bunouf P, Aubry P, Cattan S; et al. (1996). "Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry". Circulation. 94 (7): 1519–27. PMID 8840839.
- ↑ Orford JL, Lennon R, Melby S, Fasseas P, Bell MR, Rihal CS; et al. (2002). "Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry". J Am Coll Cardiol. 40 (9): 1567–72. PMID 12427407.
- ↑ Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF; et al. (1991). "Angiographic follow-up after placement of a self-expanding coronary-artery stent". N Engl J Med. 324 (1): 13–7. doi:10.1056/NEJM199101033240103. PMID 1984159.
- ↑ Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H; et al. (2006). "Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings". J Am Coll Cardiol. 47 (10): 2108–11. doi:10.1016/j.jacc.2005.11.092. PMID 16697331.
- ↑ Tsimikas S (2006). "Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited". J Am Coll Cardiol. 47 (10): 2112–5. doi:10.1016/j.jacc.2006.03.019. PMID 16697332.